<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987129</url>
  </required_header>
  <id_info>
    <org_study_id>MOP 79278</org_study_id>
    <secondary_id>200809MOP-192321</secondary_id>
    <secondary_id>CIA-CBAA-27683</secondary_id>
    <nct_id>NCT00987129</nct_id>
  </id_info>
  <brief_title>Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).</brief_title>
  <official_title>Effect of Omega-6:Omega-3 Fatty Acid Ratio on Delaying Progression of Age-related Macular Degeneration (AMD) in Moderate to High Risk Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yves Sauve</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docosahexaenoic acid (DHA) supplementation has been shown to prevent specific age-related
      changes in the retina through biochemical and functional evaluations, but it is unclear
      whether increased DHA intake-reflected through elevated DHA+EPA blood levels-can affect the
      natural history and progression of age-related macular degeneration (AMD). AMD is a disease
      affecting the macula, the part of the eye containing cone photoreceptors at the center of the
      visual field. The macula is responsible for vision in most daily functions, including
      reading, seeing fine details, and colour recognition. Severe AMD can lead to a central
      scotoma, severely impairing daily functioning. AMD can be divided into two forms: the more
      severe wet AMD, consisting of proliferation of new blood vessels in the retina, and dry AMD
      characterized by the development of drusen, a buildup of extracellular material . The
      investigators are focused on the group with the highest risk of developing the two advanced
      forms of AMD [wet AMD or central geographic atrophy]: patients with unilateral wet AMD and
      dry AMD in their other eye. The study will consist of following up a cohort of such subjects
      and monitoring their visual function in a comprehensive manner. Working in concert with
      clinical ophthalmologists and basic scientists, the investigators will monitor &quot;DHA+EPA&quot; and
      &quot;Omega6:Omega3 fatty acid ratio&quot; levels in the blood, inherited predispositions through
      genetic analysis, lipofuscin (an accumulated waste product) levels &amp; AMD progression via
      fundus photography, visual acuity, and retinal function via full-field and multifocal
      electroretinograms. These different factors will be cross-correlated and evaluated to
      determine how omega-3 fatty acids affect the progression of AMD.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient recruitment
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of dry AMD status according to international classification/grading system.</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delayed progression to neovascular AMD (NVAMD) or Central Geographic Atrophy (cGA) in the fellow eye.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood for genotyping and measuring omega-3 FA status. Serum for Cytokine level
      analysis.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Men and women with Neovascular (wet) AMD in one eye and early or intermediate dry AMD in
        the fellow eye, taking AREDS vitamins (or equivalent).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50+ years of age

          -  NVAMD (Wet) in one eye, early or intermediate dry-AMD in the fellow eye

          -  taking AREDS vitamins (or equivalent)

        Exclusion Criteria:

          -  Central geographic atrophy

          -  Diabetic retinopathy

          -  Ocular surgery in the eye with dry-AMD (not including cataract IOL surgery)

          -  Underlying ocular pathology in the eye with dry-AMD (especially glaucoma, dense
             cataracts, and retinitis pigmentosa)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Sauvé, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alberta Retina Consultants</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 0X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Chiu CJ, Klein R, Milton RC, Gensler G, Taylor A. Does eating particular diets alter the risk of age-related macular degeneration in users of the Age-Related Eye Disease Study supplements? Br J Ophthalmol. 2009 Sep;93(9):1241-6. doi: 10.1136/bjo.2008.143412. Epub 2009 Jun 9.</citation>
    <PMID>19508997</PMID>
  </reference>
  <reference>
    <citation>Cakiner-Egilmez T. Omega 3 fatty acids and the eye. Insight. 2008 Oct-Dec;33(4):20-5; quiz 26-7. Review.</citation>
    <PMID>19227095</PMID>
  </reference>
  <reference>
    <citation>Querques G, Benlian P, Chanu B, Portal C, Coscas G, Soubrane G, Souied EH. Nutritional AMD treatment phase I (NAT-1): feasibility of oral DHA supplementation in age-related macular degeneration. Eur J Ophthalmol. 2009 Jan-Feb;19(1):100-6.</citation>
    <PMID>19123156</PMID>
  </reference>
  <reference>
    <citation>SanGiovanni JP, Chew EY, Agrón E, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Klein R, Sperduto RD; Age-Related Eye Disease Study Research Group. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. Arch Ophthalmol. 2008 Sep;126(9):1274-9. doi: 10.1001/archopht.126.9.1274.</citation>
    <PMID>18779490</PMID>
  </reference>
  <reference>
    <citation>Augood C, Chakravarthy U, Young I, Vioque J, de Jong PT, Bentham G, Rahu M, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Vingerling JR, Fletcher AE. Oily fish consumption, dietary docosahexaenoic acid and eicosapentaenoic acid intakes, and associations with neovascular age-related macular degeneration. Am J Clin Nutr. 2008 Aug;88(2):398-406.</citation>
    <PMID>18689376</PMID>
  </reference>
  <reference>
    <citation>Johnson EJ, Chung HY, Caldarella SM, Snodderly DM. The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. Am J Clin Nutr. 2008 May;87(5):1521-9.</citation>
    <PMID>18469279</PMID>
  </reference>
  <reference>
    <citation>Huang LL, Coleman HR, Kim J, de Monasterio F, Wong WT, Schleicher RL, Ferris FL 3rd, Chew EY. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD. Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3864-9. doi: 10.1167/iovs.07-1420. Epub 2008 Apr 30.</citation>
    <PMID>18450596</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2009</study_first_submitted>
  <study_first_submitted_qc>September 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2009</study_first_posted>
  <last_update_submitted>January 4, 2015</last_update_submitted>
  <last_update_submitted_qc>January 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Yves Sauve</investigator_full_name>
    <investigator_title>PhD, AHFMR Senior Scholar, Ophthalmology Assistant Professor, University of Alberta</investigator_title>
  </responsible_party>
  <keyword>DHA</keyword>
  <keyword>EPA</keyword>
  <keyword>AMD</keyword>
  <keyword>drusen</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>omega6:omega3 ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

